Primemd Inc.
PRMD · OTC
12/31/2021 | 9/30/2021 | 6/30/2021 | 3/31/2021 | |
|---|---|---|---|---|
| Revenue | $2 | $3 | $5 | $1 |
| % Growth | -52.8% | -24.7% | 512.7% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $2 | $3 | $5 | $1 |
| % Margin | 100% | 100% | 100% | 100% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $0 | $4 | $4 | $0 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$2 | $0 | $0 | $0 |
| Operating Expenses | -$2 | $4 | $4 | $0 |
| Operating Income | $3 | -$0 | $0 | $1 |
| % Margin | 211.5% | -8% | 4.7% | 91.6% |
| Other Income/Exp. Net | -$1 | $0 | $0 | -$0 |
| Pre-Tax Income | $3 | $0 | $0 | $1 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | $3 | -$0 | $0 | $1 |
| % Margin | 159.9% | -10.8% | 4.8% | 88.5% |
| EPS | 0.14 | -0.02 | 0.012 | 0.036 |
| % Growth | 796.5% | -268.9% | -66.7% | – |
| EPS Diluted | 0.14 | -0.02 | 0.012 | 0.036 |
| Weighted Avg Shares Out | 18 | 19 | 18 | 19 |
| Weighted Avg Shares Out Dil | 18 | 19 | 18 | 19 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | $3 | -$0 | $0 | $1 |
| % Margin | 207.1% | -8.2% | 4.9% | 91.5% |